The state of Michigan currently has 410 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374
Recruiting
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Profound Research LLC ( Site 0074), Royal Oak, Michigan
Conditions: Triple-Negative Breast Cancer
Register for Updates
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan +72 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ā‰„ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Local Institution - Unk069, Detroit, Michigan +2 locations
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Henry Ford Health System, Detroit, Michigan +5 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771
Recruiting
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer
Register for Updates
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331
Recruiting
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: BAMF Health, Grand Rapids, Michigan
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/13/2025
Locations: Research Site, Detroit, Michigan +1 locations
Conditions: Metastatic Prostate Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693
Recruiting
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan
Conditions: Breast Cancer
Register for Updates
Precision-Based Genomics in Prostate Cancer
NCT04706663
Recruiting
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand how gene mutations relate to the way the cancer progresses and responds to treatment. Eligibility:... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Prostate Cancer
Register for Updates
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760
Recruiting
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Michigan Clinical Trials Office ( Site 0058), Ann Arbor, Michigan +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Trinity Health Saint Joseph Mercy Ann Arbor, Ann Arbor, Michigan
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
NCT04098744
Recruiting
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Gender:
FEMALE
Ages:
Between 25 years and 100 years
Trial Updated:
08/13/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Register for Updates